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ies a same combination could demonstrate synergism or
antagonism across different model systems.
The variable results of the same combination across different
tumour models is reflective of the heterogeneity of cancers,
pointing to the importance of patient selection. However, most
targeted agents were developed in unselected patients and the
activities were defined by the population average, often without
knowledge of the predictive markers. For combination regimens
with more than one targeted agent, the lack of patient selection
would not only compromise the efficiency of the clinical studies
but also make the outcome data misleading. For example,
improved efficacy of a combination may not be detectable in
the overall patient population if synergism is dependent on a spe-
cific molecular context that is only present in a small subset of
patients. Conversely, an improvement in the overall response rate
or progression free survival may not necessarily mean benefit of
the combination in individual patient, as the results may simply
reflect the summation of the outcomes of individual components
in different subsets of patients.
Also at issue is the limited guidance for optimal doses for the
combination regimens. Specifically, if dose reduction of individ-
ual agents is required for combination therapies due to safety
issues, would the combination still perform better than single
agents at full dose? In addition, it is possible to differentially
reduce the doses of the two agents and multiple MTDs may be
defined for the same combination. It is however difficult to deter-
mine which dose ratio would be optimal.
In addition the sequence of agent administrations is often
critical to the outcome of the combination, given the unique
mechanisms of actions of targeted agents. Indeed synergism of
many combination regimens has been found to be sequence-
dependent. However, not uncommonly, different tumour models
may produce conflicting results regarding the optimal sequence
for the same combination. Without knowledge of the molecular
contexts and clinical relevance of the preclinical models, it is dif-
ficult to apply these observations to clinical studies.
IMPROVING PRECLINICAL STUDIES: Clearly, more and better
preclinical and nonclinical studies are needed for overcoming
these barriers. Such non-clinical studies have the potential to
enhance our knowledge of the individual agents and their
combination, the mechanisms of actions, and markers for
responsiveness or resistance, all of which critical to optimiz-
ing the strategy for clinical development of combination regi-
mens. Nevertheless, the limitations of preclinical studies must
also be appreciated in order to appropriately use the model
systems.
Some ideas to improve preclinical studies were offered. A sys-
tematic effort is needed to molecularly characterize the human
tumours and preclinical models. Experiments for specific combi-
nations should be carried out in multiple tumour models and
include clinically relevant doses and exposures. The single-agent
control should be based on the full dose for comparison with the
combination regimen. More importantly, results should be inter-
preted in the molecular context of the models to maximize trans-
latability to the clinical settings.
One also cannot overemphasise the importance of correlative
studies for the search of predictive and pharmacodynamic mark-
ers. These correlative studies are not only important in clinical
trials but should start from non clinical studies, including those
on cell lines and animal models.
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INTRODUCTION: Cancer vaccines present unique developmen-
tal challenges. Some potential solutions exist, but they are not
widely known nor is there any consensus about their use. The
Cancer Vaccine Clinical Trial Working Group (CVCTWG), a joint
initiative of the Cancer Vaccine Consortium (CVC) and the inter-
national society for biological therapy of cancer (iSBTc), has pro-
posed a new clinical development paradigm for cancer vaccines
and immunotherapies through workshops conducted between
October 2004 and November 2005.
The goal of CTCVWG was to use collective knowledge in the
field to synthesize a flexible and applicable paradigm, reach a
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consensus on practical recommendations to improve cancer vac-
cine development, and offer an accepted, practical approach to
cancer vaccine development. To achieve these goals, 200 aca-
demic leaders, biotechnology/pharmaceutical drug developers,
and regulators attended three workshops and worked together
over the course of more than a year.
RATIONALE BEHIND A NEW PARADIGM FOR CANCER VACCINE
DEVELOPMENT: Cancer vaccines have distinctly different bio-
logic characteristics compared to cytotoxic agents and, therefore,
required an adjusted developmental approach. For example, can-
cer vaccines do not pose serious toxicity risks, and there is no
proof of a linear dose-potency relationship for cancer vaccines.
Therefore, it is not necessary to conduct a conventional dose-
escalation to establish maximum tolerated dose (MTD). Dose
and schedule are not determined through escalation based on
toxicity. Because cancer vaccines are not usually metabolized, it
is not necessary to conduct conventional pharmacokinetic stud-
ies. Many cancer vaccines are designed to address one tumour
type, obviating the need to performedmixed tumour trials for tar-
get selection. Conventional short-term response criteria (e.g.,
RECIST) are not very applicable to cancer vaccines, and historical
control comparisons on response rates are not useful. Proof-of-
principle endpoints should reflect biologic activity, including
immunogenicity. Some standard trial designs lack the flexibility
to translate new learning into late-phase trials.
In Table 1, the CVCTWG’s proposal for a new paradigm for
development of cancer vaccines is shown.1
In this paradigm, exploratory studies serve the purpose to
demonstrate proof-of-principle. Once proof-of-principle is estab-
lished, efficacy trials should begin. Ideally, such studies should
be phase II or III randomized trials. The paradigm is also applica-
ble for combination trials of vaccines and biologics or
immunomodulators.
Cancer vaccines generally exhibit little toxicity, but first-in-
man studies should include adequate toxicity testing without
overly extensive screening for unexpected toxicities. Efficacy tri-
als must be designed with stopping criteria. Generally, there is
no need to establish an MTD, but it is desirable to determine
the optimal biologic dose.
For proof-of-principle studies, biological activity is defined as
the impact of the vaccine on immune response or on the disease
under investigation. Relevant parameters include regulatory T-
cell activity or immune response against target cells, molecular
response (minimal residual disease), or any form of clinical activ-
ity (standard or modified parameters). Immunoassays should be
established, reproducible, and technically validated in the labora-
tory where used; no clinical validation is required. Technically
validated does not mean clinically validated; rather, it signifies
that assay variability has been minimized. With immunoassays,
operator inconsistency and lack of standard operating procedures
have been identified as problems. A minimum of two such assays
should be applied, with an adequate immune response defined as
two assays being positive at two or more follow-up time points.
Dr. Hoos emphasised the importance of prospectively defining
the frequency and magnitude of the immune response for the
population under study.
If all the parameters are met, and if a signal of activity of clin-
ical response, biologic activity, or immune response is detected
based on prespecified parameters, then one could move forward
with efficacy trials.
CLINICAL ENDPOINTS: The characteristics of clinical benefit for
cancer vaccines were highlighted. Generally, immune response
builds before clinical activity occurs. The onset of clinical activity
is often delayed, and slowing of disease progression or an end-
point of stable disease may bemore relevant with cancer vaccines
than shrinkage of bulky disease.
Delayed benefit (response) occurs after disease progression.
Therefore, the paradigm calls for continuing vaccination therapy
if (1) progression is not rapid and is clinically insignificant; (2) no
other therapy is immediately required; or (3) no effective therapy
is available. Crucial to this decision are the choice of patient pop-
ulation and the rapidity of progression.
Some caveats are associated with clinical endpoints: for
example, for response rates, progressive disease may occur before
detectable benefit. Delayed benefit can lead to premature discon-
tinuation. Cancer vaccines might slow progression but not cause
tumour shrinkage. Response might require more easily quantifi-
able parameters, such as biomarkers. The study design can take
these factors into account by allowing for prospective modifica-
tion of response assessment: if response is detected after initial
progression, evaluation should either not consider progressive
disease prior to response or reset the baseline to the largest
tumour volume after the initiation of treatment. The design
should also stipulate a time window during which any delayed
Table 1 – Proposed development paradigm for cancer vaccines
Phase of development Purpose
Proof-of-principle trial(s) Safety database initiated
(Exploratory trials) N > 20 Proof-of-principle: immunogenicity, biologic activity, clinical activity
Well-defined population Use established and reproducible immunoassays
No end-stage disease Dose and schedule of vaccination as feasible
Discuss continuation with regulatory agencies
Efficacy trial(s) (Randomized trials) Expansion of safety database
Allow flexibility through prospective adaptive designs Establishment of efficacy
Post-approval trial Postmarketing surveillance
Reproduced from J. Immunother 2007; 30:1–15.1
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response must occur. Most of these caveats also apply to end-
points such as progression-free survival, disease-free survival,
and time-to-progression. Overall survival is the gold standard
for efficacy trials of cancer vaccines as it is for other anticancer
therapies.
Surrogate biomarker endpoints, defined as objectively mea-
sured parameters to indicate normal or abnormal biological pro-
cesses might be used in clinical vaccine development. It is
challenging to establish biomarkers that can serve as clinical end-
points. For proof-of-principle trials, unvalidated surrogates or bio-
markers may be used to establish biologic activity, but they must
be validated to serve as efficacy endpoints. Biomarkers should be
used as frequently as possible, at least for proof-of-principle stud-
ies, to support their validation in clinical trials. We also need to
expand the repertoire of clinical endpoints for efficacy.
Efficacy trials are direct follow-ups to proof-of-principle trials.
They bridge the gap of conventional phase II trials (single arm,
conventional response rate endpoint historical control compari-
son, end-stage disease), which are not recommended for cancer
vaccines. Adaptive designs my save time (Fig. 1).
One type of design appropriate for cancer vaccines is the com-
parative, randomized phase II trial with an adaptive component
using a prospectively defined trigger point. Sample size can be
recalculated at the trigger point. This type of design can help
identify patients who might benefit most from the vaccine and
alleviates the risk of having a negative phase III study at the
end of the development process. Even if the definitive component
stands alone as a phase III trial, the development path can be
meaningfully accelerated.
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Objective:  Introduce a clinical trial design option that allows additional flexibility for development
Trigger Point characteristics:
• Must not be fully statistically powered to demonstrate superiority (pα  or pβ )
• Separate, independently powered endpoints for both analyses: less definitive trigger point and more 
definitive efficacy endpoint 
Flexibility aspects: 
• May be expanded and data combined if stringent criteria are met
• Allow for sample size re-calculation based on trigger point data 
• Allow for modification of eligibility criteria for phase III component to focus on a specific population 
• Allow for start of phase III trial either through continuation without change or protocol amendment
Other characteristics: 
• Data from phase III component not to be pooled with phase II data if population changed
• All designs and potential changes of criteria must be prospective (as far as possible) 
• If intended for product approval, regulatory consensus or special protocol assessment should occur prior to 
initiation
Exploratory 
Component
Definitive
Component (possible phase III)   
Prospective
Trigger Point 
Efficacy
Analysis
Fig. 1. Example of a randomized phase II trial with an adaptive component.
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